Skip to Main Content

Author Details

Freddie C Hamdy
University of Oxford
1987
448
81
PMIDPaper TitleJournal TitlePublished Year
37659961Reply to Bernardo Rocco and Maria Chiara Sighinolfi's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-58.Eur Urol2024
34305038Intermediate-risk Prostate Cancer-A Sheep in Wolf's Clothing?Eur Urol Oncol2023
37628903Genomic Evolution and Transcriptional Changes in the Evolution of Prostate Cancer into Neuroendocrine and Ductal Carcinoma Types.Int J Mol Sci2023
37555785Endemic statistical paradoxes in epidemiologic studies distort knowledge on prostate cancer: mitigation and caution of fallacies in prostate cancer causal epidemiological studies.Curr Opin Urol2023
38012448Delphi consensus project on prostate-specific membrane antigen (PSMA)-targeted surgery-outcomes from an international multidisciplinary panel.Eur J Nucl Med Mol Imaging2023
37792620Decision Making in Prostate Cancer.N Engl J Med2023
37945903Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.Nat Genet2023
37945903Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.Nat Genet2023
37410655Aligning germline and somatic mutations in prostate cancer. Are genetics changing practice?BJU Int2023
37363926Rbf/E2F1 control growth and endoreplication via steroid-independent Ecdysone Receptor signalling in Drosophila prostate-like secondary cells.PLoS Genet2023
37296430Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).BMC Health Serv Res2023
36695816Protocol for the TRANSLATE prospective, multicentre, randomised clinical trial of prostate biopsy technique.BJU Int2023
36648168Clinical performance of magnetic resonance imaging and biomarkers for prostate cancer diagnosis in men at high genetic risk.BJU Int2023
36912538Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.N Engl J Med2023
34762099Prostate-Specific Antigen Testing for Prostate Cancer Screening-Is the Message Getting Through?JAMA Oncol2022
35535122Precision surgery: the role of intra-operative real-time image guidance - outcomes from a multidisciplinary European consensus conference.Am J Nucl Med Mol Imaging2022
35659150Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.Eur Urol2022
36201131Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.Pharmacoeconomics2022
35948708Spatially resolved clonal copy number alterations in benign and malignant tissue.Nature2022
35213227Metabolic profiling of prostate cancer in skeletal microenvironments identifies G6PD as a key mediator of growth and survival.Sci Adv2022
34878715Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial.BJU Int2022
35322056Automated quality assessment of large digitised histology cohorts by artificial intelligence.Sci Rep2022
33420416Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer.Prostate Cancer Prostatic Dis2021
35474657Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management.BJUI Compass2021
33541309A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance.BMC Urol2021
33590768Use of intraoperative fluorescence to enhance robot-assisted radical prostatectomy.Future Oncol2021
33750684Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review.Eur Urol Oncol2021
33888445A Systematic Review of Prostate Cancer Heterogeneity: Understanding the Clonal Ancestry of Multifocal Disease.Eur Urol Oncol2021
33580906Identification of a serum biomarker signature associated with metastatic prostate cancer.Proteomics Clin Appl2021
34505829Placebo comparator group selection and use in surgical trials: the ASPIRE project including expert workshop.Health Technol Assess2021
34155340Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.Br J Cancer2021
33398198Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.Nat Genet2021
32229180Detailed Molecular and Immune Marker Profiling of Archival Prostate Cancer Samples Reveals an Inverse Association between TMPRSS2:ERG Fusion Status and Immune Cell Infiltration.J Mol Diagn2020
31910313Implications of celebrity endorsement of prostate cancer awareness in a tertiary referral unit - the 'Fry-Turnbull' effect.BJU Int2020
31732677Prostate-Specific Membrane Antigen-Guided Surgery.J Nucl Med2020
32776451A new Editorial Team for the BJU International⿦.BJU Int2020
32773013Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.Health Technol Assess2020
32624282Erratum to 'Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received' [European Urology 77 (2020) 320-330].Eur Urol2020
32907896Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial.BMJ Open2020
32591433Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.J Immunother Cancer2020
32641865Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.Br J Cancer2020
32781078Outreach and Influence of Surgical Societies' Recommendations on Minimally Invasive Surgery During the COVID-19 Pandemic-An Anonymized International Urologic Expert Inquiry.Urology2020
32720716Glutamine deprivation alters the origin and function of cancer cell exosomes.EMBO J2020
32444265Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis.Eur Urol2020
32145797Considerations and methods for placebo controls in surgical trials (ASPIRE guidelines).Lancet2020
32514134The effect of sample size on polygenic hazard models for prostate cancer.Eur J Hum Genet2020
32231998Transcriptomic and Functional Screens Reveal MicroRNAs That Modulate Prostate Cancer Metastasis.Front Oncol2020
30622367Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.Nat Genet2019
30113754Prostatic capsular incision during radical prostatectomy has important oncological implications: a systematic review and meta-analysis.BJU Int2019
31589603Mating induces switch from hormone-dependent to hormone-independent steroid receptor-mediated growth in Drosophila secondary cells.PLoS Biol2019
  • 1 - 50 of 448

Recommended Authors

Northwestern University Feinberg School of Medicine
Career Start Year 2013
Number of shared co-authors 9
IRCCS San Raffaele Scientific Institute, Italy Vita-Salute San Raffaele University
Career Start Year 2012
Number of shared co-authors 20
University of Michigan Medical School ann arbor
Career Start Year 2012
Number of shared co-authors 14
university of california san diego School of Medicine
Career Start Year 2011
Number of shared co-authors 3
Vanderbilt University Medical Center
Career Start Year 2008
Number of shared co-authors 17
University of Texas Health San Antonio
Career Start Year 2008
Number of shared co-authors 13
Mount Sinai Hospital, University of Toronto, University Health Network
Career Start Year 2007
Number of shared co-authors 10
University of Alberta
Career Start Year 2007
Number of shared co-authors 8
University of Washington Medical Center
Career Start Year 2005
Number of shared co-authors 19
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 12
Northwestern University
Career Start Year 2003
Number of shared co-authors 30
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 35
University of Basel, Academic Hospital Braunschweig
Career Start Year 1998
Number of shared co-authors 11
Erasmus MC Cancer Institute, University Medical Center
Career Start Year 1998
Number of shared co-authors 46
Karolinska Institute
Career Start Year 1995
Number of shared co-authors 39
CHU de Quebec-Universite Laval
Career Start Year 1994
Number of shared co-authors 18
David Geffen School of Medicine at university of california los angeles
Career Start Year 1993
Number of shared co-authors 35
Washington State University Elson S. Floyd College of Medicine
Career Start Year 1992
Number of shared co-authors 11
University of Colorado School of Medicine
Career Start Year 1991
Number of shared co-authors 15
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 1990
Number of shared co-authors 20
University of Montreal Health Center
Career Start Year 1990
Number of shared co-authors 44
Monash University
Career Start Year 1988
Number of shared co-authors 37
University of Melbourne
Career Start Year 1988
Number of shared co-authors 19
Liverpool University Hospitals
Career Start Year 1988
Number of shared co-authors 17
Amsterdam University Medical Centers, University of Amsterdam
Career Start Year 1987
Number of shared co-authors 19
Johns Hopkins University School of Medicine
Career Start Year 1984
Number of shared co-authors 28
University of Western Ontario
Career Start Year 1982
Number of shared co-authors 12
University of Washington School of Medicine
Career Start Year 1980
Number of shared co-authors 24
CHU de Quebec-Universite Laval
Career Start Year 1975
Number of shared co-authors 26
University of Toronto, University Health Network
Career Start Year 1971
Number of shared co-authors 16

Collaborators

University of Oxford, John Radcliffe Hospital
Co-authored papers 217
The Institute of Cancer Research
Co-authored papers 58
The Institute of Cancer Research
Co-authored papers 58
University of Cambridge
Co-authored papers 53
Co-authored papers 39
Karolinska Institute
Co-authored papers 36
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 33
Co-authored papers 32
Co-authored papers 31
Fred Hutchinson Cancer Research Center
Co-authored papers 30
Institute of Biomedicine, University of Turku
Co-authored papers 30
University of Southern California
Co-authored papers 30
Co-authored papers 29
Co-authored papers 28
Mayo Clinic
Co-authored papers 28
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 27
Co-authored papers 26
Co-authored papers 23
Oncogenetics Team The Institute of Cancer Research London UK.
Co-authored papers 22
QIMR Berghofer Medical Research Institute
Co-authored papers 21
Co-authored papers 21
National Cancer Institute, National Institutes of Health
Co-authored papers 20
University of Oxford
Co-authored papers 20
University of Bristol
Co-authored papers 20
Co-authored papers 19
Mayo Clinic
Co-authored papers 19
Co-authored papers 19
Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine
Co-authored papers 19
University of Southern California
Co-authored papers 18
Co-authored papers 18